3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma, Ewing
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Myeloid, Acute
1
Interventions
Rituximab
18
Cyclophosphamide
17
Prednisone
12
Doxorubicin
12
Vincristine
9
Lenalidomide
7
ibrutinib
6
obinutuzumab
5
glofitamab
5
Magnetic Resonance Spectroscopy
5
polatuzumab vedotin
4
fludarabine
4
Prednisolone
4
Oxaliplatin
4
Gemcitabine
4
Etoposide
4
venetoclax
3
pembrolizumab
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
prednylidene
2
deltacortene
2
acalabrutinib
2
Mycophenolic Acid
2
Ifosfamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
etoposide phosphate
×
30 days
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled